Rani Therapeutics Holdings, Inc. (RANI)
$0.85+$0.01 (+1.19%) TodayExtended Hours
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
https://www.ranitherapeutics.comSEC filings for RANI on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 71,000 | $50K |
| Open-market sale | 1 | 386 | $301 |
| Grant or award | 5 | 7,658,200 | |
| Tax withholding / forfeiture | 1 | 309 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
31 Form 4 filings on record, the earliest from Oct 17, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Michelle Gilson - Director | Grant or award | Director Stock Option (Right to Buy) | 247,200 | $0.00 | - | |
| Mir A. Imran | Open-market purchase | Class A Common Stock | 36,000 | $0.69 | $25K | |
| Alireza Javadi - Officer | Open-market sale | Class A Common Stock | 386 | $0.78 | $301 | |
| Alireza Javadi - Officer | Tax withholding / forfeiture | Class A Common Stock | 309 | $0.74 | $229 | |
| Talat Imran - Officer | Open-market purchase | Class A Common Stock | 35,000 | $0.72 | $25K | |
 Nicholas Maestas - Officer | Grant or award | Stock Option (Right to Buy) | 2,000,000 | $0.00 | - | |
| Kate McKinley - Officer | Grant or award | Stock Option (Right to Buy) | 805,500 | $0.00 | - | |
| Alireza Javadi - Officer | Grant or award | Stock Option (Right to Buy) | 805,500 | $0.00 | - | |
| Talat Imran - Officer | Grant or award | Stock Option (Right to Buy) | 3,800,000 | $0.00 | - | |
| Abraham Bassan | Grant or award | Director Stock Option (Right to Buy) | 123,600 | $0.00 | - | |
| Lisa Ann Rometty | Grant or award | Director Stock Option (Right to Buy) | 123,600 | $0.00 | - | |
| Mir A. Imran | Grant or award | Director Stock Option (Right to Buy) | 123,600 | $0.00 | - | |
| Jean Luc Butel | Grant or award | Director Stock Option (Right to Buy) | 123,600 | $0.00 | - | |
| Vasudev Jaiprakash Bailey | Grant or award | Director Stock Option (Right to Buy) | 123,600 | $0.00 | - | |
 Dennis A. Ausiello | Grant or award | Director Stock Option (Right to Buy) | 123,600 | $0.00 | - | |
| Vasudev Jaiprakash Bailey | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Mir A. Imran | Open-market purchase | Class A Common Stock | 2,083,334 | $0.61 | $1.26M | |
| Mir A. Imran | Open-market purchase | Warrant to Purchase Class A Common Stock | 2,083,334 | $0.00 | - | |
| Abraham Bassan | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| South Cone Investments Limited Partnership - 10% Owner | Open-market sale | Class A Common Stock | 1,923,000 | $2.41 | $4.64M | |
| South Cone Investments Limited Partnership - 10% Owner | Open-market sale | Class A Common Stock | 4,000,000 | $2.77 | $11.07M | |
| Kate McKinley - Officer | Grant or award | Employee Stock Option (Right to Buy) | 120,000 | $0.00 | - | |
| Jean Luc Butel | Grant or award | Director Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Mir A. Imran | Grant or award | Director Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Andrew Farquharson | Derivative | Stock Option (Right to Buy) | 101,276 | - | - | |
| Andrew Farquharson | Grant or award | Stock Option (Right to Buy) | 101,276 | - | - | |
| Lisa Ann Rometty | Derivative | Stock Option (Right to Buy) | 101,276 | - | - | |
| Lisa Ann Rometty | Grant or award | Stock Option (Right to Buy) | 101,276 | - | - | |
| Lisa Ann Rometty | Derivative | Stock Option (Right to Buy) | 17,708 | - | - | |
| Lisa Ann Rometty | Grant or award | Stock Option (Right to Buy) | 17,708 | - | - | |
| Maulik Nanavaty | Derivative | Stock Option (Right to Buy) | 101,276 | - | - | |
| Maulik Nanavaty | Grant or award | Stock Option (Right to Buy) | 101,276 | - | - | |
| Maulik Nanavaty | Derivative | Stock Option (Right to Buy) | 15,423 | - | - | |
| Maulik Nanavaty | Grant or award | Stock Option (Right to Buy) | 15,423 | - | - | |
| Dennis A. Ausiello | Derivative | Stock Option (Right to Buy) | 101,276 | - | - | |
| Dennis A. Ausiello | Grant or award | Stock Option (Right to Buy) | 101,276 | - | - | |
| Dennis A. Ausiello | Derivative | Stock Option (Right to Buy) | 15,423 | - | - | |
| Dennis A. Ausiello | Grant or award | Stock Option (Right to Buy) | 15,423 | - | - | |
| Jean Luc Butel | Derivative | Stock Option (Right to Buy) | 101,276 | - | - | |
| Jean Luc Butel | Grant or award | Stock Option (Right to Buy) | 101,276 | - | - | |
| Jean Luc Butel | Derivative | Stock Option (Right to Buy) | 18,875 | - | - | |
| Jean Luc Butel | Grant or award | Stock Option (Right to Buy) | 18,875 | - | - | |
| Laureen Debuono | Derivative | Stock Option (Right to Buy) | 101,276 | - | - | |
| Laureen Debuono | Grant or award | Stock Option (Right to Buy) | 101,276 | - | - | |
| Laureen Debuono | Derivative | Stock Option (Right to Buy) | 18,875 | - | - | |
| Laureen Debuono | Grant or award | Stock Option (Right to Buy) | 18,875 | - | - | |
| Mir A. Imran | Derivative | Stock Option (Right to Buy) | 101,276 | - | - | |
| Mir A. Imran | Grant or award | Stock Option (Right to Buy) | 101,276 | - | - | |
| Kate McKinley - Officer | Open-market purchase | Class A Common Stock | 17,960 | $1.67 | $30K | |
| Talat Imran - Officer | Open-market purchase | Class A Common Stock | 10,296 | $1.94 | $20K |
Rani Therapeutics Holdings, Inc. (RANI) had 8 insider filings in the last 90 days, with the most recent on 2026-08-05. The full record for RANI runs to 31 Form 4 filings, the earliest from 2024-10-17. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
2 insider purchases of RANI were filed in the last 90 days, totaling $50K.
1 insider sale of RANI was filed in the last 90 days, totaling $301.
This page tracks RANI Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add RANI to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
